Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness. A Phase 2/3 study failed earlier this year, but Abcuro saw positive trends in patients with less severe disease.
The post Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs appeared first on MedCity News.
